Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 4, 2008, Pages 411-423

  Kelly, Marcus P ^a   Lee, F T ^a   Tahtis, Kiki ^a   Power, Barbara E ^b   Smyth, Fiona E ^a   Brechbiel, Martin W ^c   Hudson, Peter J ^b   Scott, Andrew M ^a  

^a AUSTIN HOSPITAL   (Australia)

^b CSIRO   (Australia)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Biodistribution; hu3S193; Lewis Y antigen; scFv multimeric construct

Indexed keywords

INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HU 3S193; POLYMER; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; FEMALE; GENE CONSTRUCT; IMMUNOREACTIVITY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOASSAY; TISSUE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; AREA UNDER CURVE; CELL LINE, TUMOR; CHROMATOGRAPHY, GEL; DRUG STABILITY; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; INDIUM RADIOISOTOPES; LEWIS BLOOD-GROUP SYSTEM; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; RADIONUCLIDE IMAGING; RECOMBINANT PROTEINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 51349152085     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0450     Document Type: Article

References (49)

1. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006;6:343.
2. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126.
3. Sharkey RM, Karacay H, Cardillo TM, et al. Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 2005;11:7109s.
4. Wu AM, Senter PD. Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137.
5. Jostock T, Vanhove M, Brepoels E, et al. Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J Immunol Meth 2004;289:65.
6. 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med 2006;47:716.
7. Zhang S, Zhang HS, Cordon-Cardo C, et al. Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer 1997;73:50.
8. Scott AM, Tebbutt N, Lee F-T, et al. Phase I trial of hu3S193 in patients with advanced epithelial cancers which express the Lewis Y antigen. [Meeting Abstracts] J Clin Oncol 2004;22:2567.
9. Scott AM, Geleick D, Rubira M, et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 2000;60:3254.
10. Clarke K, Lee FT, Brechbiel MW, et al. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 2000;60:4804.
11. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46(Suppl. 1):115S.
12. Buchsbaum DJ, Rogers BE, Khazaeli MB, et al. Targeting strategies for cancer radiotherapy. Clin Cancer Res 1999;5:3048s.
13. Adams GP, Schier R. Generating improved single-chain Fv molecules for tumor targeting. J Immunol Meth 1999;231:249.
14. Batra SK, Jain M, Wittel UA, et al. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol 2002;13:603.
15. 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur J Nucl Med Mol Imaging 2005;32:264.
16. Kortt AA, Dolezal O, Power BE, et al. Dimeric and trimeric antibodies: High avidity scFvs for cancer targeting. Biomol Eng 2001;18:95.
17. Hudson PJ, Souriau C. Engineered antibodies. Nat Med 2003;9:129.
18. Huhalov A, Chester KA. Engineered single-chain antibody fragments for radioimmunotherapy. Q J Nucl Med Mol Imaging 2004;48:279.
19. Wittel UA, Jain M, Goel A, et al. The in vivo characteristics of genetically engineered divalent and tetravalent single-chain antibody constructs. Nucl Med Biol 2005;32:157.
20. 99mTc-labeled divalent and tetravalent CC49 single-chain Fvs: Novel imaging agents for rapid in vivo localization of human colon carcinoma. J Nucl Med 2001;42:1519.
21. Power BE, Doughty L, Shapira DR, et al. Noncovalent scFv multimers of tumor-targeting anti-Lewis(y) hu3S193 humanized antibody. Protein Sci 2003;12:734.
22. Power BE, Hudson PJ. Synthesis of high-avidity antibody fragments (scFv multimers) for cancer imaging. J Immunol Meth 2000;242:193.
23. Tahtis K, Lee FT, Smyth FE, et al. Biodistribution properties of (111)indium-labeled C-functionalized transcyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab′)(2) constructs in a breast carcinoma xenograft model. Clin Cancer Res 2001;7:1061.
24. Todorovska A, Roovers RC, Dolezal O, et al. Design and application of diabodies, triabodies, and tetrabodies for cancer targeting. J Immunol Meth 2001;248:47.
25. Goel A, Colcher D, Baranowska-Kortylewicz J, et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: Improved biodistribution and potential for therapeutic application. Cancer Res 2000;60:6964.
26. Scott AM, Lee F-T, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: Biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005;11:4810.
27. Wu C, Kobayashi H, Sun B, et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem 1997;5:1925.
28. Nikula TK, Curcio MJ, Brechbiel MW, et al. A rapid, single-vessel method for preparation of clinical grade ligand conjugated monoclonal antibodies. Nucl Med Biol 1995;22:387.
29. 131I-labeled multivalent CC49 single-chain fvs. Clin Cancer Res 2001;7:175.
30. Duncan JR, Welch MJ. Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins. J Nucl Med 1993;34:1728.
31. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res 1996;56:2123.
32. Huang B-C, Foote LJ, Lankford TK, et al. A diabody that dissociates to monomer forms at low concentration: effects on binding activity and tumor targeting. Biochem Biophys Res Commun 2005;327:999.
33. 2 fragments of human monoclonal IgM (16.88) in a nude mouse model. Nucl Med Biol 1995;22:413.
34. 2 fragments in mice. Int J Cancer 1997;72:522.
35. Behr TM, Sharkey RM, Juweid ME, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825.
36. Arano Y, Fujioka Y, Akizawa H, et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res 1999;59:128.
37. Behe M, Kluge G, Becker W, et al. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys. J Nucl Med 2005;46:1012.
38. Gansow OA, Brechbiel MW, Mirzadeh S, et al. Chelates and antibodies: Current methods and new directions. Cancer Treat Res 1990;51:153.
39. Ferl GZ, Kenanova V, Wu AM, et al. A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments. Mol Cancer Ther 2006;5:1550.
40. Liu X-Y, Pop LM, Roopenian DC, et al. Generation and characterization of a novel tetravalent anti-CD22 antibody with improved antitumor activity and pharmacokinetics. Int Immunopharmacol 2006;6:791.
41. Rothlisberger D, Honegger A, Pluckthun A. Domain interactions in the Fab fragment: A comparative evaluation of the single-chain Fv and Fab format engineered with variable domains of different stability. J Mol Biol 2005;347:773.
42. Wark KL, Hudson PJ. Latest technologies for the enhancement of antibody affinity. Adv Drug Del Rev 2006;58:657.
43. Brinkmann U, Di Carlo A, Vasmatzis G, et al. Stabilization of a recombinant Fv fragment bybase-loop interconnection and VH-VL permutation. J Mol Biol 1997;268:107.
44. Dall'Acqua W, Carter P. Antibody engineering. Curr Opin Struct Biol 1998;8:443.
45. Le Gall F, Reusch U, Little M, et al. Effect of linker sequences between the antibody variable domains on the formation, stability, and biological activity of a bispecific tandem diabody. Protein Eng Des Sel 2004;17:357.
46. Olafsen T, Cheung CW, Yazaki PJ, et al. Covalent disulfide-linked Anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor-targeting applications. Protein Eng Des Sel 2004;17:21.
47. Reusch U, Le Gall F, Hensel M, et al. Effect of tetravalent bispecific CD19 X CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B-cells from patients with chronic lymphocytic leukemia by autologous T cells. Int J Cancer 2004;112:509.
48. Zhu Z, Presta LG, Zapata G, et al. Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 1997;6:781.
49. Deyev SM, Waibel R, Lebedenko EN, et al. Design of multivalent complexes using the barnase*barstar module. Nat Biotechnol 2003;21:1486.